---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-031637"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:32:13.925538+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NRx subsidiary HOPE Therapeutics acquires minority interest in Cohen & Associates; Dr. Cohen named Medical Director

## Summary
- HOPE Therapeutics acquired strategic minority interest in Rebecca S. Cohen, MD, LLC (Cohen & Associates) of Sarasota, FL, effective Oct 17, 2025.
- Dr. Rebecca Cohen appointed Medical Director of HOPE Therapeutics, overseeing medical standards in Florida locations.
- Cohen & Associates offers TMS, ketamine, and medication management for depression, PTSD, and CNS disorders.
- Immediate expansion planned in Western Florida and Palm Beach.
- Acquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA.

## SEC filing metadata
- accession: 0001437749-25-031637
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925031637/0001437749-25-031637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925031637/nrxp20251023_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-031637
- JSON: https://secwatch.observer/filing/0001437749-25-031637.json
- Plain text: https://secwatch.observer/filing/0001437749-25-031637.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.